Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Healthcare | Biotechnology | Netherlands
statements
Index- P/E- EPS (ttm)-2.99 Insider Own1.40% Shs Outstand44.28M Perf Week6.98%
Market Cap2.93B Forward P/E- EPS next Y-3.76 Insider Trans-25.92% Shs Float38.98M Perf Month6.15%
Income-124.40M PEG- EPS next Q-0.80 Inst Own95.40% Short Float11.69% Perf Quarter30.51%
Sales6.20M P/S473.04 EPS this Y-32.80% Inst Trans1.71% Short Ratio11.55 Perf Half Y19.78%
Book/sh6.67 P/B10.07 EPS next Y-19.40% ROA-31.40% Target Price85.56 Perf Year16.78%
Cash/sh7.83 P/C8.58 EPS next 5Y- ROE-45.20% 52W Range36.20 - 82.49 Perf YTD-6.28%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-33.70% 52W High-18.58% Beta1.29
Dividend %- Quick Ratio12.90 Sales past 5Y3.50% Gross Margin- 52W Low85.52% ATR3.42
Employees248 Current Ratio12.90 Sales Q/Q-90.90% Oper. Margin- RSI (14)66.06 Volatility6.19% 5.19%
OptionableYes Debt/Eq0.00 EPS Q/Q14.20% Profit Margin- Rel Volume1.26 Prev Close63.02
ShortableYes LT Debt/Eq0.12 EarningsMar 12 BMO Payout- Avg Volume394.29K Price67.16
Recom1.70 SMA209.88% SMA5021.94% SMA20021.12% Volume497,754 Change6.57%
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-12-19Initiated Mizuho Buy
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Nov-26-18Reiterated H.C. Wainwright Buy $48 → $60
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
May-16-18Initiated Wells Fargo Outperform $47
May-07-18Reiterated Leerink Partners Outperform $26 → $63
Jan-04-18Initiated Janney Buy $25
May-18-20 07:49AM  Analysts Have Just Cut Their uniQure N.V. (NASDAQ:QURE) Revenue Estimates By 16% Simply Wall St.
May-14-20 07:00AM  uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting GlobeNewswire
May-11-20 11:13PM  JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era Bloomberg
Apr-29-20 08:45AM  UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM  uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire
Apr-28-20 04:51PM  uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting GlobeNewswire
Apr-27-20 12:32PM  Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline Zacks
Apr-24-20 04:21PM  Why Sanofi CEO's Comments Lit A Fire Under Gene Therapy Stocks Investor's Business Daily +9.03%
Apr-21-20 10:47AM  Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet? Simply Wall St.
Apr-17-20 07:00AM  uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors GlobeNewswire
Mar-30-20 07:00AM  uniQure to Participate in Multiple Upcoming Investor Conferences in April GlobeNewswire
Mar-28-20 09:10PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Mar-26-20 12:36PM  Biotech delays U.S. gene therapy launch due to outbreak, FDA discord American City Business Journals
07:00AM  uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B GlobeNewswire
Mar-18-20 06:01AM  Biotech pushes blood disorder cell therapy to clinic after $80M round American City Business Journals
Mar-03-20 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in March GlobeNewswire
Mar-02-20 05:45PM  UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.65%
04:05PM  uniQure Announces 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
04:05PM  uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters GlobeNewswire
Feb-27-20 07:00AM  uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDIs 15th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire
Feb-26-20 08:41AM  Why Earnings Season Could Be Great for uniQure (QURE) Zacks
Feb-21-20 10:48AM  Before You Buy uniQure N.V. (NASDAQ:QURE), Consider Its Volatility Simply Wall St.
Feb-20-20 12:31PM  UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Feb-04-20 07:00AM  uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) GlobeNewswire
Jan-31-20 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in February GlobeNewswire
Jan-10-20 02:20PM  Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
Jan-07-20 12:12PM  uniQure (NASDAQ:QURE) Shareholders Have Enjoyed A Magnificent 1077% Share Price Gain Simply Wall St.
Dec-24-19 09:30AM  BioMarin Files BLA for Gene Therapy to Treat Hemophilia A Zacks
Dec-19-19 10:27AM  One particular field of drug development could dominate M&A in 2020 American City Business Journals
07:00AM  uniQure Announces Publication of Preclinical Data for AMT-130 in Huntingtons Disease Supporting Non-Selective HTT-Lowering Approach GlobeNewswire
Dec-17-19 09:11AM  5 Biotech Stocks That Have More Than Doubled This Year Zacks
07:02AM  Will uniQure Continue to Surge Higher? Zacks
06:00AM  Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-16-19 09:34AM  5 Biotech Stocks Set for Continued Rally in 2020 Zacks
Dec-08-19 04:00PM  uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire
Dec-06-19 09:33AM  The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
10:12AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
03:49AM  Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 09:42AM  Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga +16.68%
Dec-02-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in December GlobeNewswire
Nov-30-19 07:02PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Nov-22-19 10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
Nov-07-19 09:45AM  uniQure N.V. (QURE) Shares March Higher, Can It Continue? Zacks
Nov-06-19 09:16AM  uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-05-19 07:00AM  uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy GlobeNewswire
Nov-01-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in November GlobeNewswire
Oct-31-19 07:00AM  uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec GlobeNewswire
Oct-30-19 11:46AM  Are Insiders Selling uniQure N.V. (NASDAQ:QURE) Stock? Simply Wall St.
10:38AM  uniQure N.V. (QURE) Shares March Higher, Can It Continue? Zacks
Oct-29-19 12:37PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Oct-28-19 08:15AM  UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Oct-25-19 09:15AM  S&P, NASDAQ Up Again in Mixed Session Zacks +7.41%
Oct-02-19 09:33AM  Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO American City Business Journals
Oct-01-19 01:43PM  Biotech Roundtable: How to Invest in Medicines Future Barrons.com -5.67%
Sep-30-19 11:10AM  Is uniQure N.V.'s (NASDAQ:QURE) CEO Pay Justified? Simply Wall St.
Sep-27-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in October GlobeNewswire
Sep-26-19 10:34AM  Hedge Fund P.A.W. Capital Partners Top Stock Picks Insider Monkey -6.36%
Sep-05-19 08:39PM  uniQure Announces Pricing of its Public Offering GlobeNewswire -14.86%
08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 04:02PM  uniQure Announces Proposed Public Offering GlobeNewswire
Sep-03-19 07:00AM  uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B GlobeNewswire
Aug-30-19 08:32AM  uniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry? Simply Wall St.
07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences in September GlobeNewswire
Aug-20-19 07:00AM  uniQure Announces Leadership Promotions and Executive Transition GlobeNewswire
Aug-16-19 06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Jul-31-19 06:28AM  Introducing uniQure (NASDAQ:QURE), The Stock That Soared 653% In The Last Three Years Simply Wall St.
Jul-29-19 08:35AM  UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.38%
07:18AM  uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Jul-26-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jul-19-19 12:15PM  Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares GuruFocus.com
Jul-11-19 05:33AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised) Zacks
Jul-09-19 11:07AM  Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study Zacks
Jul-08-19 08:19AM  What Drove uniQure 171% Higher in the First Half of 2019 Motley Fool
Jul-06-19 07:00AM  uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B GlobeNewswire
Jul-02-19 06:02AM  How Much Of uniQure N.V. (NASDAQ:QURE) Do Institutions Own? Simply Wall St.
Jun-29-19 08:25AM  The Week Ahead In Biotech: Pending Clinical Readouts In Focus Benzinga
Jun-22-19 09:33PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Jun-21-19 07:00AM  uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) GlobeNewswire
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-17-19 04:21PM  Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst Investor's Business Daily +11.84%
09:41AM  Gene-Therapy Firm UniQure Explores Options Including Sale Bloomberg
09:33AM  UniQure Jumps on Report It's Exploring a Possible Sale TheStreet.com
Jun-11-19 08:47AM  Is the Options Market Predicting a Spike in uniQure (QURE) Stock? Zacks -12.02%
Jun-05-19 11:53AM  AMD and 3 more momentum stocks to watch MarketWatch
07:08AM  An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued Simply Wall St.
Jun-04-19 09:01AM  uniQure (QURE) Jumps: Stock Rises 8.9% Zacks +9.44%
May-31-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-22-19 07:00AM  uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntingtons Disease GlobeNewswire
May-10-19 04:16PM  This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study Investor's Business Daily +6.67%
02:44PM  uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling Simply Wall St.
08:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
May-07-19 07:00AM  uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting GlobeNewswire
May-02-19 04:26PM  Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ? Insider Monkey
07:00AM  uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting GlobeNewswire
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorMay 20Sale59.947,501449,580311,041May 22 05:13 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Option Exercise26.412,25059,42359,268Apr 28 04:29 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Sale60.002,250135,00057,018Apr 28 04:29 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Option Exercise7.539,37670,601327,918Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Sale56.879,376533,205318,542Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Option Exercise7.535,62642,364324,168Mar 20 01:16 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Sale41.485,626233,352318,542Mar 20 01:16 PM
KLEMT CHRISTIANChief Accounting OfficerMar 04Option Exercise26.4115,750415,95872,768Mar 06 10:07 AM
KLEMT CHRISTIANChief Accounting OfficerMar 04Sale52.2915,750823,50057,018Mar 06 10:07 AM
Kapusta Matthew CCEO, CFO, Managing DirectorFeb 19Sale64.567,501484,256284,753Feb 21 10:03 AM
Soteropoulos PaulaDirectorFeb 05Sale60.952,122129,3322,423Feb 05 01:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 31Sale57.983,872224,499264,541Jan 31 03:45 PM
Astley-Sparke PhilipDirectorJan 30Sale59.2380747,7996,005Jan 30 09:39 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 30Sale59.3123,5831,398,646268,413Jan 31 03:45 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 29Sale61.9423,5831,460,794291,996Jan 31 03:45 PM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 28Sale62.141,47891,84840,100Jan 30 09:36 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale61.9223,5831,460,221315,579Jan 29 11:24 AM
Kaye JackDirectorJan 28Sale62.2080650,13314,128Jan 30 09:32 PM
Balachandran MadhavanDirectorJan 28Sale62.2080750,1956,005Jan 30 09:23 PM
Soteropoulos PaulaDirectorJan 28Sale62.1980750,1874,545Jan 30 09:15 PM
van Deventer SanderEVP, Research & Product Dev.Jan 28Sale61.612,227137,21443,127Jan 30 09:11 PM
SCHAFFER DAVIDDirectorJan 28Sale62.2780650,19044,915Jan 30 09:06 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale61.4711,975736,07242,564Jan 30 09:02 PM
Springhorn Jeremy P.DirectorJan 28Sale62.1980750,1906,005Jan 30 08:57 PM
Meek David D.DirectorJan 28Sale62.1972244,9032,508Jan 30 08:54 PM
Gut RobertChief Medical OfficerJan 28Sale62.1959637,06527,885Jan 29 06:02 PM
Gut RobertChief Medical OfficerJan 27Sale60.016,897413,88928,481Jan 29 06:02 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale65.5528,2891,854,280339,162Jan 29 11:24 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Option Exercise5.314,00021,24045,578Jan 17 09:39 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Sale68.974,000275,88041,578Jan 17 09:39 AM
Soteropoulos PaulaDirectorJan 07Sale72.183,000216,5405,352Jan 08 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Option Exercise7.537,33955,263374,991Dec 20 04:13 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Sale70.097,540528,510367,451Dec 20 04:13 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Option Exercise5.314,00021,24045,578Dec 17 04:09 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Sale74.594,000298,35641,578Dec 17 04:09 PM
Soteropoulos PaulaDirectorDec 13Option Exercise5.372,00010,74010,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 13Sale70.502,000141,0008,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 09Sale67.502,500168,7508,352Dec 09 06:30 PM
Soteropoulos PaulaDirectorDec 06Sale64.269,082583,60010,852Dec 09 06:30 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 20Sale53.748,000429,951367,652Nov 22 10:12 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Option Exercise5.314,00021,24045,578Nov 19 08:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsNov 15Sale52.084,000208,31041,578Nov 19 08:51 AM
Kapusta Matthew CCEO, CFO, Managing DirectorOct 23Sale43.228,000345,781375,652Oct 25 08:38 AM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Option Exercise5.314,00021,24045,578Oct 17 01:21 PM
Kuta Alexander Edward IIIExecutive VP, OperationsOct 15Sale42.354,000169,40041,578Oct 17 01:21 PM
Gut RobertChief Medical OfficerSep 19Sale47.164,769224,90635,378Sep 20 02:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorSep 18Sale47.318,000378,486383,652Sep 20 01:49 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Option Exercise5.314,00021,24030,578Sep 18 01:25 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 16Sale47.264,000189,04026,578Sep 18 01:25 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 21Sale56.488,000451,840391,230Aug 23 10:43 AM
Astley-Sparke PhilipDirectorAug 01Sale60.126,460388,3446,812Aug 05 12:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 17Sale71.458,000571,616399,230Jul 19 10:37 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 19Sale77.458,000619,626407,230Jun 20 11:03 AM
Astley-Sparke PhilipDirectorJun 03Sale63.636,000381,77913,272Jun 04 02:07 PM
open in yahoo | open in reuters | open in google